My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 654

    1.

    Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression.

    Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T, Kobayashi M.

    Diabetes. 2007 Mar;56(3):795-803.PMID: 17327450 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes.

    Ishizuka K, Usui I, Kanatani Y, Bukhari A, He J, Fujisaka S, Yamazaki Y, Suzuki H, Hiratani K, Ishiki M, Iwata M, Urakaze M, Haruta T, Kobayashi M.

    Endocrinology. 2007 Jun;148(6):2994-3003. Epub 2007 Mar 22.PMID: 17379643 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.

    Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, Kawahara J, Ueno E, Sasaoka T, Ishibashi O, Kobayashi M.

    Diabetes. 2001 May;50(5):1083-92.PMID: 11334412 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects.

    Rotter V, Nagaev I, Smith U.

    J Biol Chem. 2003 Nov 14;278(46):45777-84. Epub 2003 Sep 2.PMID: 12952969 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Long-term interleukin-1alpha treatment inhibits insulin signaling via IL-6 production and SOCS3 expression in 3T3-L1 adipocytes.

    Uno T, He J, Usui I, Kanatani Y, Bukhari A, Fujisaka S, Yamazaki Y, Suzuki H, Iwata M, Ishiki M, Urakaze M, Haruta T, Ogawa H, Kobayashi M.

    Horm Metab Res. 2008 Jan;40(1):8-12. Epub 2007 Dec 17.PMID: 18085494 [PubMed - indexed for MEDLINE]Related articles

    6.

    Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling.

    Shi H, Tzameli I, Bjørbaek C, Flier JS.

    J Biol Chem. 2004 Aug 13;279(33):34733-40. Epub 2004 Jun 4.PMID: 15181014 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.

    Dallaire P, Bellmann K, Laplante M, Gélinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A.

    Diabetes. 2008 Aug;57(8):1999-2011. Epub 2008 May 5.PMID: 18458147 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.

    Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S.

    Hepatology. 2009 May;49(5):1636-44.PMID: 19205029 [PubMed - indexed for MEDLINE]Related articles

    9.

    Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.

    Nakano S, Inada Y, Masuzaki H, Tanaka T, Yasue S, Ishii T, Arai N, Ebihara K, Hosoda K, Maruyama K, Yamazaki Y, Shibata N, Nakao K.

    Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1213-22. Epub 2006 Dec 26.PMID: 17190905 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects.

    Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U.

    Diabetologia. 2005 Jan;48(1):96-104. Epub 2004 Dec 29.PMID: 15624096 [PubMed - indexed for MEDLINE]Related articles

    11.

    Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.

    Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, Tse HF, Fong CH, Tam S, Chan L, Lam KS.

    Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2777-82. Epub 2007 Oct 11.PMID: 17932317 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.

    Li YY, Wu HS, Tang L, Feng CR, Yu JH, Li Y, Yang YS, Yang B, He QJ.

    Pharmacol Res. 2007 Oct;56(4):335-43. Epub 2007 Aug 9.PMID: 17889553 [PubMed - indexed for MEDLINE]Related articles

    13.

    Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance.

    Shi H, Cave B, Inouye K, Bjørbaek C, Flier JS.

    Diabetes. 2006 Mar;55(3):699-707.PMID: 16505233 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes.

    Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, Olefsky JM.

    J Biol Chem. 2005 Oct 21;280(42):35361-71. Epub 2005 Aug 5.PMID: 16085647 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase.

    Pereira RI, Leitner JW, Erickson C, Draznin B.

    Life Sci. 2008 Nov 7;83(19-20):638-43. Epub 2008 Sep 16.PMID: 18824177 [PubMed - indexed for MEDLINE]Related articles

    16.

    Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.

    Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T.

    J Biol Chem. 2006 Mar 31;281(13):8748-55. Epub 2006 Jan 23.PMID: 16431926 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes.

    Kim KY, Kim JK, Jeon JH, Yoon SR, Choi I, Yang Y.

    Biochem Biophys Res Commun. 2005 Feb 11;327(2):460-7.PMID: 15629137 [PubMed - indexed for MEDLINE]Related articles

    18.

    A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

    Eur J Pharmacol. 2008 Apr 14;584(1):192-201. Epub 2008 Feb 14.PMID: 18346728 [PubMed - indexed for MEDLINE]Related articles

    19.

    Insulin resistance-inducing cytokines differentially regulate SOCS mRNA expression via growth factor- and Jak/Stat-signaling pathways in 3T3-L1 adipocytes.

    Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R.

    J Endocrinol. 2004 Apr;181(1):129-38.PMID: 15072573 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression.

    Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T.

    J Biol Chem. 2004 Nov 12;279(46):47626-32. Epub 2004 Aug 31.PMID: 15339912 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity